Please assess the completion status of the following clinical trial:

Trial Title: Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 18-75 years of age at Screening~2. Has ALS symptom onset within 2 years prior to Screening~3. Has forced vital capacity (FVC) no higher than 60% at screening~4. If taking riluzole, is on a stable dose for 4 weeks before Screening~Exclusion Criteria:~1. Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any type~2. Has used any medication within a time period not allowed per protocol~3. Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant infection~4. Used edaravone less than 1 week before Screening~5. Received any stem cell replacement therapy~6. Used steroids within a time period not allowed per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Treatment Period Acthar (Type: EXPERIMENTAL): Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39.
- Arm B: Treatment Period Placebo (Type: PLACEBO_COMPARATOR): Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39.
- Arm C: Extension Period Acthar-Acthar (Type: EXPERIMENTAL): Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
- Arm D: Extension Period Placebo-Acthar (Type: EXPERIMENTAL): Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).